Earnings ·
MannKind reports Q3 revenue of $101.9 million, up 24% year-over-year
MNKDMannkind Corp
MannKind Corporation reported third-quarter 2026 total revenues of $101.9 million, a 24% increase from the prior-year period. Commercial product sales reached $45.0 million, driven by Furoscix net revenue of $22.4 million and Afrezza net sales of $19.3 million. The company recorded a net loss of $23.2 million for the quarter, compared to net income of $8.0 million in Q3 2025. MannKind is a biopharmaceutical company focused on developing and commercializing treatments for cardiometabolic and orphan lung diseases.